Biogen Idec Inc (NASDAQ:BIIB): Institutional Investor Sentiment Down to 0.7

Biogen Inc. (NASDAQ:BIIB) Logo

Sentiment for Biogen Idec Inc (NASDAQ:BIIB)

Biogen Idec Inc (NASDAQ:BIIB) institutional sentiment decreased to 0.7 in Q2 2019. Its down -0.18, from 0.88 in 2019Q1. The ratio fall, as 280 active investment managers increased and opened new holdings, while 398 decreased and sold stakes in Biogen Idec Inc. The active investment managers in our partner’s database now possess: 153.48 million shares, down from 163.29 million shares in 2019Q1. Also, the number of active investment managers holding Biogen Idec Inc in their top 10 holdings decreased from 14 to 10 for a decrease of 4. Sold All: 82 Reduced: 316 Increased: 202 New Position: 78.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $43.65 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 8.82 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

The stock increased 1.86% or $4.32 during the last trading session, reaching $236.63. About 1.45M shares traded or 1.04% up from the average. Biogen Inc. (NASDAQ:BIIB) has declined 28.25% since September 13, 2018 and is downtrending. It has underperformed by 28.25% the S&P500.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on October, 22. They expect $8.24 EPS, up 11.35 % or $0.84 from last year’s $7.4 per share. BIIB’s profit will be $1.52 billion for 7.18 P/E if the $8.24 EPS becomes a reality. After $9.15 actual EPS reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -9.95 % negative EPS growth.

Sarissa Capital Management Lp holds 18.75% of its portfolio in Biogen Inc. for 643,000 shares. Krensavage Asset Management Llc owns 176,556 shares or 13.4% of their US portfolio. Moreover, Sector Gamma As has 4.33% invested in the company for 115,126 shares. The California-based Saratoga Research & Investment Management has invested 3.53% in the stock. Waverton Investment Management Ltd, a United Kingdom-based fund reported 253,331 shares.

Since January 1, 0001, it had 1 buying transaction, and 0 selling transactions for $27.21 million activity.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Ratings analysis reveals 32% of Biogen Inc’s analysts are positive. Out of 19 Wall Street analysts rating Biogen Inc, 6 give it “Buy”, 1 “Sell” rating, while 12 recommend “Hold”. The lowest target is $19800 while the high is $416. The stock’s average target of $270.84 is 14.46% above today’s ($236.63) share price. BIIB was included in 31 notes of analysts from March 20, 2019. The rating was maintained by Guggenheim on Thursday, March 21 with “Hold”. The company was downgraded on Thursday, March 21 by Bank of America. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Buy” rating by Raymond James on Tuesday, March 26. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Thursday, March 21 by Cantor Fitzgerald. On Thursday, May 9 the stock rating was maintained by Barclays Capital with “Equal-Weight”. BMO Capital Markets maintained it with “Hold” rating and $250 target in Friday, March 22 report. Stifel Nicolaus maintained the shares of BIIB in report on Thursday, March 21 with “Hold” rating. The firm has “Neutral” rating given on Friday, March 22 by Mizuho. The rating was downgraded by Piper Jaffray to “Neutral” on Friday, June 28. The rating was maintained by Cowen & Co with “Buy” on Thursday, March 21.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Finance.Yahoo.com which released: “Better Buy: Biogen vs. Celgene – Yahoo Finance” on August 25, 2019, also Nasdaq.com with their article: “Amgen’s KRAS Inhibitor Shows Response in Larger NSCLC Group – Nasdaq” published on September 09, 2019, 247Wallst.com published: “Major Biotechs Scare Off Short Sellers – 24/7 Wall St.” on September 12, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth – Nasdaq” published on April 17, 2019 as well as Nasdaq.com‘s news article titled: “Amgen (AMGN) Soars to 52-Week High, Time to Cash Out? – Nasdaq” with publication date: August 14, 2019.

Biogen Inc. (NASDAQ:BIIB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.